Eli Lilly and Co (LLY)
806.14
-12.79
(-1.56%)
USD |
NYSE |
Nov 04, 16:00
804.99
-1.15
(-0.14%)
Pre-Market: 06:37
Eli Lilly Cash from Financing (Quarterly): 211.30M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 211.30M |
| June 30, 2024 | 1.556B |
| March 31, 2024 | -311.30M |
| December 31, 2023 | 3.545B |
| September 30, 2023 | 572.00M |
| June 30, 2023 | -1.033B |
| March 31, 2023 | 412.30M |
| December 31, 2022 | -1.141B |
| September 30, 2022 | -1.263B |
| June 30, 2022 | -123.70M |
| March 31, 2022 | -2.878B |
| December 31, 2021 | -1.526B |
| September 30, 2021 | -463.20M |
| June 30, 2021 | -1.083B |
| March 31, 2021 | -1.058B |
| December 31, 2020 | -1.292B |
| September 30, 2020 | -279.10M |
| June 30, 2020 | -1.673B |
| March 31, 2020 | 106.70M |
| December 31, 2019 | -1.114B |
| September 30, 2019 | -1.693B |
| June 30, 2019 | -885.80M |
| March 31, 2019 | 1.368B |
| December 31, 2018 | -1.640B |
| September 30, 2018 | 432.70M |
| Date | Value |
|---|---|
| June 30, 2018 | -831.40M |
| March 31, 2018 | -3.866B |
| December 31, 2017 | -542.30M |
| September 30, 2017 | 500.70M |
| June 30, 2017 | 1.060B |
| March 31, 2017 | -875.70M |
| December 31, 2016 | 385.20M |
| September 30, 2016 | -600.10M |
| June 30, 2016 | 579.30M |
| March 31, 2016 | -924.20M |
| December 31, 2015 | -871.40M |
| September 30, 2015 | -595.20M |
| June 30, 2015 | -943.20M |
| March 31, 2015 | -701.20M |
| December 31, 2014 | 1.537B |
| September 30, 2014 | -405.90M |
| June 30, 2014 | -702.50M |
| March 31, 2014 | -595.10M |
| December 31, 2013 | -1.036B |
| September 30, 2013 | -529.00M |
| June 30, 2013 | -533.80M |
| March 31, 2013 | -1.730B |
| December 31, 2012 | -1.265B |
| September 30, 2012 | -544.70M |
| June 30, 2012 | -552.70M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-2.878B
Minimum
Mar 2022
3.545B
Maximum
Dec 2023
-441.88M
Average
-748.30M
Median
Cash from Financing (Quarterly) Benchmarks
| Amgen Inc | -3.651B |
| Johnson & Johnson | -9.882B |
| Merck & Co Inc | 1.216B |
| Viking Therapeutics Inc | 2.522M |
| Moderna Inc | 34.00M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 3.712B |
| Cash from Investing (Quarterly) | -4.005B |
| Free Cash Flow | -2.275B |
| Free Cash Flow Per Share (Quarterly) | -0.5071 |
| Free Cash Flow to Equity (Quarterly) | -2.687B |
| Free Cash Flow to Firm (Quarterly) | -370.39M |
| Free Cash Flow Yield | -0.31% |